Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

January 24, 2020January 29, 2020

Tests with Hand Function Tasks Better for Assessing Scleroderma Progression, Treatment Response, Study Finds

News

Women with scleroderma take longer to perform daily living tasks, especially those that require hand strength and gripping objects, such as moving things between shelves, a new study found. ... Read more

December 2, 2019December 2, 2019

Health Canada Approves Ofev to Help Preserve Lung Health in People with SSc-ILD

News

Health Canada has approved Ofev (nintedanib) as a treatment to slow the decline of pulmonary function in people with scleroderma-associated interstitial lung disease (SSc-ILD). The approval makes Ofev, by Boehringer Ingelheim, the first treatment ... Read more

November 4, 2019November 4, 2019

Skin Lesions Develop Soon After Onset of Raynaud’s Phenomenon, 10-year Follow-up Study Reports

News

Most people with scleroderma develop skin lesions within one year after the onset of Raynaud’s phenomenon (RP), a condition in which the fingers and toes feel numb, prickly, and ... Read more

October 16, 2019October 16, 2019

One-Year Cytoxan Treatment Improves Lung Function in Scleroderma-ILD Patients, Trials Show

News

Treatment for one year with the immunosuppressant Cytoxan (cyclophosphamide) improves lung function in scleroderma patients with interstitial lung disease (SSc-ILD) — but these benefits wear off after stopping treatment, data from ... Read more

August 26, 2019August 26, 2019

Newer EUSTAR-AI Scale Ably Predicts Short-term Risk of SSc Progression, Study Finds

News

The European Scleroderma Trials and Research Group (EUSTAR) revised activity index scale, known as EUSTAR-AI, is the best tool for predicting the short-term risk of disease progression and severe ... Read more

August 12, 2019August 12, 2019

Sarcopenia May Affect up to 55% of Patients with SSc, Study Suggests

News

Loss of muscle mass and strength — known as sarcopenia — may affect up to 55% of patients with systemic sclerosis (SSc), a study suggests. Moreover, sarcopenia was found ... Read more

August 9, 2019August 9, 2019

High Levels of IL-6 Correlate with More Severe Skin Disease in SSc, Study Shows

News

Levels of a pro-inflammatory signaling molecule, called interleukin (IL)-6, are significantly high in skin lesions and blood samples of patients with systemic sclerosis (SSc), especially among those with diffuse ... Read more

August 5, 2019August 5, 2019

ACE Inhibitors Raise Risk of Renal Crisis in Some SSc Patients, Study Says

News

Systemic sclerosis (SSc) patients with elevated protein in their urine (proteinuria) who are using angiotensin-converting enzyme (ACE) inhibitors (ACEi) are at higher risk of developing scleroderma renal crisis (SRC), ... Read more

July 17, 2019July 17, 2019

Rituximab’s Immunosuppressive Effects Go Beyond B Cells in SSc, Study Finds

News

Rituximab, an immunosuppressant antibody designed to target immune B cells, has widespread effects and decreases subtypes of other immune cells called T cells in the skin and blood of ... Read more

July 3, 2019July 3, 2019

Levels of Two Blood Proteins Predict Course of ILD in SSc, Data Suggest

News

High levels of two proteins in the blood, called KL-6 and CCL-18, may work as biomarkers for predicting disease severity and progression of interstitial lung disease (ILD) in systemic sclerosis ... Read more

Pin It on Pinterest